ORLEANS, ON, May 30, 2018 /CNW Telbec/ - Tetra
Bio-Pharma Inc. ("Tetra" or
the "Corporation") (TSXV: TBP) (OTCQB: TBPMF), a global
leader in cannabinoid-based drug development and discovery, is
pleased to announce that a total of 11,500,000 common share
purchase warrants (the "Warrants") of the Corporation will
be listed and posted for trading under the symbol TBP.WT on the TSX
Venture Exchange effective on or about June
1, 2018.
The Warrants were issued in connection with the Company's bought
deal prospectus offering of Units (the "Units") that closed
on March 5, 2018. Each Unit consisted
of one common share (a "Common Share") and one Warrant.
Each Warrant entitles the holder thereof to purchase one Common
Share at an exercise price equal to $1.30 at any time before March 5, 2021.
The Warrants are governed by the terms of a Warrant Indenture
dated March 5, 2018 between the
Company and Computershare Trust Company of Canada as warrant agent, a copy of which is
available under the Company's profile at www.sedar.com. For further
details regarding the Warrants, please refer to the Warrant
Indenture.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a
biopharmaceutical leader in cannabinoid-based drug discovery and
development with a clinical program aimed at bringing novel drugs
and treatments to patients and their healthcare providers. The
Company has several subsidiaries that are engaged in the
development of Bio Pharmaceuticals and Natural Health Products
containing Cannabis and other medicinal plant based elements.Tetra
Bio-Pharma is focused on combining the traditional methods of
medicinal cannabis use with the supporting scientific validation
and safety data required for inclusion into the existing bio pharma
industry by regulators, physicians and insurance companies.
More information at: www.tetrabiopharma.com
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking statements
Some statements in this
release may contain forward-looking information. All statements,
other than of historical fact, that address activities, events or
developments that the Corporation believes, expects
or anticipates will or may occur in the future (including, without
limitation, statements regarding potential acquisitions and
financings) are forward-looking statements. Forward-looking
statements are generally identifiable by use of the words "may",
"will", "should", "continue", "expect", "anticipate", "estimate",
"believe", "intend", "plan" or "project" or the negative of these
words or other variations on these words or comparable terminology.
Forward-looking statements are subject to a number of risks and
uncertainties, many of which are beyond the
Corporation's ability to control or predict, that may
cause the actual results of the Corporation to differ
materially from those discussed in the forward-looking statements.
Factors that could cause actual results or events to differ
materially from current expectations include, among other things,
without limitation, the failure to obtain sufficient financing to
execute the Corporation's business plan; the success
of the Rx PrincepsTM product offering and inhalation
device; guidance on expected sales volumes associated with the Rx
PrincepsTM product offering and inhalation device;
competition; regulation and anticipated and unanticipated costs and
delays, and other risks disclosed in the
Corporation's public disclosure record on file with the
relevant securities regulatory authorities. Although the
Corporation has attempted to identify important factors
that could cause actual results or events to differ materially from
those described in forward-looking statements, there may be other
factors that cause results or events not to be as anticipated,
estimated or intended. Readers should not place undue reliance on
forward-looking statements. The forward-looking statements included
in this news release are made as of the date of this news release
and the Corporation does not undertake an obligation
to publicly update such forward-looking statements to reflect new
information, subsequent events or otherwise unless required by
applicable securities legislation.
SOURCE Tetra Bio-Pharma Inc.